NLX-112, a highly selective 5-HT1A receptor biased agonist, does not exhibit misuse potential in male rats or macaques
Sign Up to like & getrecommendations! Published in 2022 at "Neuropharmacology"
DOI: 10.1016/j.neuropharm.2022.109025
Abstract: NLX-112 (a.k.a. F13640 or befiradol) exhibits nanomolar affinity, exceptional selectivity and biased agonism at serotonin 5-HT1A receptors. NLX-112 displays robust analgesic activity in a number of rodent models of pain, and is currently developed as… read more here.
Keywords: misuse potential; ht1a; nlx 112; icss ... See more keywords